KITLG and intrahepatic cholangiocarcinoma: Amelioration of altered TP/nucleosides metabolism by HSCT [20], gene therapy [70], orthotopic liver transplantation [74], or enzyme replacement therapy [75] (reviewed in [3]), singular or in combination with strategies focusing on overcoming the deficits of SCF/c-Kit pathways or VSICs, could be beneficial as preventive measures to maintain the quality and quantity of- and prevent further damage of intestinal ICC/ ICC networks (Fig. 1).